Manabu Yamamoto

Dr. Manabu Yamamoto

Osaka Metropolitan University, Ōsaka, Japan
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2016 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
AYAyako Yasui
Ayako Yasui
Manabu YamamotoManabu Yamamoto
Manabu Yamamoto
KHKumiko Hirayama
Kumiko Hirayama
KSKunihiko Shiraki
Kunihiko Shiraki
DTDirk Theisen-Kunde
Dirk Theisen-Kunde
TKTakeya Kohno
Takeya Kohno

26 April 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAkika Kyo
Akika Kyo
Manabu YamamotoManabu Yamamoto
Manabu Yamamoto
KHKumiko Hirayama
Kumiko Hirayama
TKTakeya Kohno
Takeya Kohno
DTDirk Theisen-Kunde
Dirk Theisen-Kunde
SHShigeru Honda
Shigeru Honda
The purpose of this study was to investigate the factors of clinical outcome of selective retina therapy (SRT) for central serous chorioretinopathy (CSC). This retrospective study included 77 eyes of 77 patients, who were treated with SRT for CSC and observed at least 6 months after the treatment. SRT laser (527 nm, 1.7 µs, 100 Hz) was used for treatment. The mean best-corrected visual acuity (logMAR), central macular thickness (CMT) and central choroidal thickness were changed from baseline to at 6-months follow-up with significant difference. The multivariate analyses found that the rate of change (reduction) in CMT was associated with focal leakage type on fluorescein angiography (FA) (p = 0.03, coefficient 15.26, 95% confidence interval 1.72–28.79) and larger baseline CMT (p < 0.01, coefficient − 0.13, 95% confidence interval − 0.13 to − 0.05). Complete resolution of subretinal fluid was associated with nonsmoking history (p = 0.03, odds ratio 0.276, 95% confidence interval 0.086–0.887) and focal leakage type on FA (p < 0.01, odds ratio 0.136, 95% confidence interval 0.042–0.437). These results may be useful for predicting the therapeutic effectiveness of SRT.

16 January 2020 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
Manabu YamamotoManabu Yamamoto
Manabu Yamamoto
YMYoko Miura
Yoko Miura
KHKumiko Hirayama
Kumiko Hirayama
TKTakeya Kohno
Takeya Kohno
DKDaijiro Kabata
Daijiro Kabata
SHShigeru Honda
Shigeru Honda

1 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SHSatoshi Honda
Satoshi Honda
TKTakeya Kohno
Takeya Kohno
Manabu YamamotoManabu Yamamoto
Manabu Yamamoto
KHKumiko Hirayama
Kumiko Hirayama
AKAkika Kyo
Akika Kyo
SHShigeru Honda
Shigeru Honda
The purpose of this study was to investigate the occurrence rate and predictors of photodynamic therapy (PDT) induced acute exudative maculopathy (PAEM). This retrospective study included 39 eyes of 39 patients (32 males and 7 females), who were treated with initial PDT. PAEM was defined as an increase in central retinal thickness (CRT) of 15% or more measured by OCT on day 3 after PDT compared with baseline. Sixteen of 39 eyes (41%) were classified in the PAEM+ group. CRT and central choroidal thickness (CCT) were significantly increased at 3 days in the PAEM+ group and significantly decreased at 1 month after PDT in the PAEM- group. In a multiple comparison, neovascular age-related macular degeneration (nAMD) had a significantly higher incidence of PAEM compared to polypoidal choroidal vasculopathy (PCV) and central serous chorioretinopathy (CSC). The incidence of PAEM was lower in PCV and CSC, and higher in nAMD. BCVA at 1 month was significantly worse in the PAEM group, which may be related to visual prognosis after PDT. Since both CRT and CCT decrease at 1 month, the detection of PAEM needs to be assessed a few days after PDT.

Verified
Journal Article
Open access
PDF file
Manabu YamamotoManabu Yamamoto
Manabu Yamamoto
KHKumiko Hirayama
Kumiko Hirayama
AKAkika Kyo
Akika Kyo
GKGen Kinari
Gen Kinari
YKYuki Kojima
Yuki Kojima
Shigeru HondaShigeru Honda
Shigeru Honda
Objectives: To evaluate the immediate and short-term changes in intraocular pressure (IOP) following intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) agents and to identify the clinical and procedural factors associated with IOP elevation after treatment. Methods: This retrospective study included 118 eyes from 115 patients who underwent IVI with anti-VEGF agents at Osaka Metropolitan University Hospital between September 2024 and January 2025. IOP was measured at three time points, namely before injection, within 1 min after injection, and at 30 min, in selected eyes with a post-injection IOP ≥ 25 mmHg. Differences in IOP elevation were analyzed according to the disease type and anti-VEGF agent. Univariate and multivariate linear regression analyses were performed to identify clinical factors associated with IOP elevation. Results: Mean IOP significantly increased from 13.9 ± 3.3 mmHg at baseline to 39.2 ± 12.4 mmHg immediately after injection (p < 0.001), with 79.7% of eyes showing an IOP ≥ 25 mmHg. Among those remeasured, IOP decreased to 17.7 ± 6.5 mmHg at 30 min. Significant differences in IOP elevation were observed among anti-VEGF agents (p < 0.001), with aflibercept at 2 mg and 8 mg showing greater increases than other agents. Multivariate analysis identified higher baseline IOP, history of glaucoma, absence of prior vitrectomy, and use of aflibercept (2 mg or 8 mg) as significant risk factors for greater post-injection IOP elevation. Conclusions: Transient IOP elevation ≥ 25 mmHg was observed in the majority of eyes after IVI but typically resolved within 30 min. Aflibercept use, high baseline IOP, glaucoma history, and absence of prior vitrectomy were associated with greater IOP elevation. Careful monitoring and attention to injection volume may be warranted, particularly in high-risk patients.

Verified
Journal Article
Open access
PDF file
KHKumiko Hirayama
Kumiko Hirayama
Manabu YamamotoManabu Yamamoto
Manabu Yamamoto
Shigeru HondaShigeru Honda
Shigeru Honda
AKAkika Kyo
Akika Kyo
NMNorihiko Misawa
Norihiko Misawa
TKTakeya Kohno
Takeya Kohno
Objective: To purpose of this study was to retrospectively evaluate the 1-year outcomes and factors associated with the treatment responsiveness of switching to intravitreal brolucizumab (IVBR) for neovascular age-related macular degeneration (nAMD) in Japanese patients refractory to ranibizumab or aflibercept using a treat and extend (TAE) regimen. Methods: A total of 48 eyes of 47 nAMD patients were switched to IVBR, and 36 eyes of 35 patients (27 males and 8 females) underwent 1-year treatment after the switch. Results: The rate of dry macula was significantly higher 12 months after the switch to IVBR (p < 0.001), with a significant decrease in the mean central macular thickness (CMT) and the mean central choroidal thickness (CCT) (p < 0.01 and p < 0.01, respectively). The injection interval was significantly extended from 7.0 ± 1.7 weeks to 10.3 ± 2.5 weeks 12 months after the switch (p < 0.001). In the multivariate analysis, a smaller number of prior anti-VEGF injections (p = 0.025; odds ratio: 0.947; 95% confidence interval: 0.903–0.994) and a pre-switching CCT of less than 250 µm (p = 0.023; odds ratio: 0.099; 95% confidence interval: 0.013–0.731) were associated with the good response group. Conclusions: These results suggest that IVBR may suppress disease activity and prolong the injection interval by switching for AMD patients with an insufficient response to treatment with ranibizumab and aflibercept.